EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Trinity Biotech's Enterprise Value is €159.28 Mil.
Trinity Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €-10.49 Mil. Therefore, Trinity Biotech's EV-to-FCF for today is -15.19.
The historical rank and industry rank for Trinity Biotech's EV-to-FCF or its related term are showing as below:
FRA:TRB0'
s EV-to-FCF Range Over the Past 10 Years
Min: -31.02 Med: -12.04 Max: 24.54
Current: -11.57
During the past 13 years, the highest EV-to-FCF of Trinity Biotech was 24.54. The lowest was -31.02. And the median was -12.04.
FRA:TRB0's EV-to-FCF is ranked worse than 100% of 414
companies
in the Medical Devices & Instruments industry
Industry Median: 23.19
vs FRA:TRB0: -11.57
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Trinity Biotech's PE Ratio (TTM) for today is calculated as:
Trinity Biotech's share price for today is €2.12.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Trinity Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-1.719.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Trinity Biotech EV-to-FCF Related Terms
Trinity Biotech EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Trinity Biotech's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:TRB0 vs AIDX, NVNO, STME: EV-to-FCF Comparison
For the Medical Devices subindustry, Trinity Biotech's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Trinity Biotech EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Trinity Biotech's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Trinity Biotech's EV-to-FCF falls into.
Trinity Biotech's current Enterprise Value is €159.28 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Trinity Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €-10.49 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Trinity Biotech (FRA:TRB0) has a EV-to-FCF of -15.19 as of Jul. 12, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Trinity Biotech and its competitors. According to the industry distribution chart, Trinity Biotech ranks #999999 out of 414 companies in the Medical Devices & Instruments industry.
Is Trinity Biotech's EV-to-FCF too high?
Trinity Biotech's current EV-to-FCF is -15.19. Based on the distribution chart, Trinity Biotech ranks #999999 out of 414 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Trinity Biotech has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Trinity Biotech's EV-to-FCF compare to AIDX and NVNO?
According to the Medical Devices & Instruments industry distribution chart, Trinity Biotech ranks #999999 out of 414 companies for EV-to-FCF. This places Trinity Biotech in the lower half of its industry. The industry median EV-to-FCF is 23.19. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.19, based on 414 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Trinity Biotech and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Trinity Biotech's current EV-to-FCF is -15.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Trinity Biotech stock overvalued right now?
Trinity Biotech (FRA:TRB0) has a current EV-to-FCF of -15.19. The stock's GF Value™ is €4.10, compared to a current price of €2.12 — trading 48.3% below its estimated fair value. The current EV-to-FCF is -15.19. Trinity Biotech's overall GF Score™ is 26/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Trinity Biotech (FRA:TRB0), the current EV-to-FCF is -15.19 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Trinity Biotech (FRA:TRB0) Overvalued in 2026?
Based on GuruFocus' analysis, Trinity Biotech stock appears to be undervalued.
The current stock price of €2.12 is trading 48.3% below its estimated GF Value™ of €4.10.
Key valuation signals for FRA:TRB0:
EV-to-FCF: -15.19
GF Value™: €4.10 vs. price of €2.12 (48.3% below fair value)
No single metric tells the full story. See the FRA:TRB0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has three segments, namely the Americas, Asia/Africa, and Europe, from which it derives a majority of its revenue from the Americas segment.
26GF Score
Get the complete analysis for FRA:TRB0
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:TRB0 has been successfully added to your 
